Drug class profile · refreshed daily from federal data

Macrolide (Antibiotic)

1 molecule in this class, $72.6M combined CY2024 Part D spend across 13.7M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Macrolide (Antibiotic) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $72.6Mcombined across class
Total Rx claims: 13.7M10.3M unique beneficiaries
Generic mfrs (active): 20across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Azithromycin

Brand: AZASITE · 13.7M Part D claims (CY24) · 10.3M beneficiaries · First FDA approval: 1995-10-19

20 generic mfrs 33 plans require PA Discontinued

Low NADAC$0.214

→

Avg plan cost$1.74

Part D spend $72.6M 8× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.